论文部分内容阅读
目的探讨雷贝拉唑联合莫沙必利治疗反流性食管炎的临床疗效。方法选取2012年4月-2013年9月来医院治疗的反流性食管炎患者158例,随机分为观察组和对照组各79例,对照组给予基础治疗+雷贝拉唑治疗,观察组在对照组基础上给予莫沙必利治疗,治疗1个月后观察2组临床疗效。结果观察组总有效率为97.47%明显高于对照组的82.28%,差异有统计学意义(P<0.05)。观察组胃镜下检查总有效率为98.73%明显高于对照组的79.75%,差异有统计学意义(P<0.05)。结论雷贝拉唑联合莫沙必利治疗反流性食管炎可全天维持抑酸水平,增强胃肠道运动,改善患者的胃肠道症状,且安全性高,值得临床推广应用。
Objective To investigate the clinical efficacy of rabeprazole combined with mosapride in the treatment of reflux esophagitis. Methods A total of 158 patients with reflux esophagitis who were hospitalized from April 2012 to September 2013 were randomly divided into observation group (79 cases) and control group (79 cases). The control group received basic therapy plus rabeprazole. The observation group Mosapride treatment was given on the basis of the control group, and the clinical efficacy was observed after 1 month of treatment. Results The total effective rate was 97.47% in the observation group was significantly higher than 82.28% in the control group, the difference was statistically significant (P <0.05). The total effective rate of observation group was 98.73% under gastroscope was significantly higher than 79.75% of the control group, the difference was statistically significant (P <0.05). Conclusion Rabeprazole combined with mosapride treatment of reflux esophagitis can maintain acid suppression throughout the day, enhance gastrointestinal motility and improve gastrointestinal symptoms in patients with high safety, it is worthy of clinical promotion and application.